Therapeutic Advances in Hematology

Papers
(The median citation count of Therapeutic Advances in Hematology is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Prognostic impact of IL7R mutations on acute myeloid leukemia38
Brain iron content and cognitive function in patients with β-thalassemia32
BEST study: one-year descriptive follow-up of bevacizumab treatment in hereditary haemorrhagic telangiectasia post-BABH interventional study29
Real-world study of use patterns and clinical outcomes for patients with myelodysplastic syndrome initiating oral decitabine and cedazuridine or intravenous/subcutaneous hypomethylating agents28
Effective engraftment via granulocyte transfusion in pre-engraftment febrile neutropenia following allogeneic hematopoietic stem cell transplantation: granulocyte transfusion as bridge therapy21
Integrated genetic, epigenetic, and immune landscape of TP53 mutant AML and higher risk MDS treated with azacitidine19
Role of abatacept in the prevention of graft-versus-host disease: current perspectives16
A comparison of the effect of three different comorbidity indices on overall survival in patients with chronic myeloid leukemia16
Macrofocal multiple myeloma in the era of novel agents in China16
Treatment of multiple myeloma: What is the impact on T-cell function?14
Efficacy and safety of Busulfan–Fludarabine versus Busulfan–Cyclophosphamide as a conditioning regimen prior to hematopoietic stem cell transplant in hematologic malignancy patients: a meta-analysis o14
Efficacy and safety of immunosuppressive therapy in connective tissue disease-related immune thrombocytopenia: a systematic review and meta-analysis13
Successful maintenance of a sustained molecular response in CML patients receiving low-dose tyrosine kinase inhibitors13
Outcomes and effect of somatic mutations after erythropoiesis stimulating agents in patients with lower-risk myelodysplastic syndromes12
Real-world clinical outcomes of autologous stem cell transplantation in Chinese patients with newly diagnosed multiple myeloma: a systematic literature review12
Comparison of eltrombopag and avatrombopag in the treatment of refractory/relapsed aplastic anemia: a single-center retrospective study in China11
Recombinant factor IX Fc prophylaxis reduces pain and increases levels of physical activity, with sustained, long-term improvements in patients with hemophilia B: post hoc analysis of phase III10
Therapy for patients with chronic phase-chronic myeloid leukemia previously treated with ⩾2 tyrosine kinase inhibitors: a systematic literature review10
Thanks to Reviewers10
Safety and efficacy of luspatercept in treating anemia associated with myelodysplastic syndrome with ring sideroblasts in Asian patients who require red blood cell transfusions: a phase II bridging st10
Marstacimab for People with Severe Hemophilia A or Moderate to Severe Hemophilia B Without Inhibitors: A Plain Language Summary of Publication of the BASIS Study9
Advancements in minimal residual disease detection: a practical approach using single-cell droplet PCR for comprehensive monitoring in hematological malignancy9
Real-world usage and effectiveness of recombinant factor IX Fc in haemophilia B from the B-SURE study in France9
How to translate and implement the current science of gene therapy into haemophilia care?9
Successful rechallenge with Erwinia chrysanthemi asparaginase after pegaspargase-induced hypertriglyceridemia: a case report8
Anemia is associated with long-term exposure to PM2.5 and its components: a large population-based study in Southwest China8
Histamine dihydrochloride and low-dose interleukin-2 in an emerging landscape of relapse prevention in acute myeloid leukemia8
Use and positioning of fostamatinib in the management of primary chronic immune thrombocytopenia: an Italian expert opinion8
Efficacy and safety of anti-CD38 monoclonal antibodies-based therapy versus standard therapy in newly diagnosed multiple myeloma patients: a systematic review and meta-analysis8
Corrigendum to “Real-world use of recombinant porcine sequence factor VIII in the treatment of acquired hemophilia A: EU PASS”7
The efficacy and safety of asciminib treatment in patients with chronic myeloid leukemia as a second-line or beyond second-line treatment: a systematic review and meta-analysis7
A systematic review and meta-analysis of carfilzomib-associated thrombocytopenia as an adverse event in patients with multiple myeloma7
Between Charybdis and Scylla—an Odyssey in AL amyloidosis: insights and learnings from a narrative review and case report series7
Non-invasive prenatal testing for fetal Ss, Kidd, and CTL2 blood group prediction by multiplex digital droplet PCR7
Phase I/II results of ceralasertib as monotherapy or in combination with acalabrutinib in high-risk relapsed/refractory chronic lymphocytic leukemia7
Superior survival outcome of blinatumomab compared with conventional chemotherapy for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia: a propensity score–match7
Interferons in the treatment of myeloproliferative neoplasms7
Calculated haemorheological profile and laboratory parameters in new diagnosed multiple myeloma patients: retrospective analysis according to survival7
Association of CVAI, LAP and SMI with risk of haematological toxicity after immunochemotherapy in patients with DLBCL: a retrospective study7
A new beginning: can omidubicel emerge as the next, viable alternative donor source?7
Efficacy and safety of venetoclax-based regimens for the treatment of relapsed/refractory multiple myeloma: a systemic review and meta-analysis7
Demographics, clinical characteristics, and real-world treatment patterns among patients with beta-thalassemia: a retrospective medical record abstraction study6
Real-world efficacy and tolerability of ixazomib-based combination therapies in advanced multiple myeloma and other plasma cell neoplasms6
Individualized decitabine dosing for post-HSCT maintenance in MDS and secondary AML from MDS: long-term outcomes from the PODAC trial and matched controls6
Assessment of risk factors for acute graft-versus-host disease post-hematopoietic stem cell transplantation: a retrospective study based on a proportional odds model using a nonlinear mixed-eff6
Efficacy of complement inhibitors for patients with paroxysmal nocturnal hemoglobinuria: a systematic review and meta-analysis6
Avatrombopag treatment response in patients with immune thrombocytopenia: the REAL-AVA 1.0 study5
Single-center experience of venetoclax combined with azacitidine in young patients with newly diagnosed acute myeloid leukemia5
Application and investigation of thrombopoiesis-stimulating agents in the treatment of thrombocytopenia5
Efficacy of therapeutic strategies on thrombocytopenia after hematopoietic stem cell transplantation—an evidence-based meta-analysis5
Outcomes of SARS-CoV-2 infection in Ph-neg chronic myeloproliferative neoplasms: results from the EPICOVIDEHA registry5
Prognostic significance of MRD and its correlation with arsenic concentration in pediatric acute promyelocytic leukemia: a retrospective study by SCCLG-APL group5
Risk factors and prognosis of thrombocytopenia in people living with HIV/AIDS4
Frontline treatment of IDH1-mutated myelodysplastic syndrome with ivosidenib: clinical cases and therapeutic insights4
Rilzabrutinib versus placebo in adults and adolescents with persistent or chronic immune thrombocytopenia: LUNA 3 phase III study4
Nine areas with outstanding challenges for hemophilia B research4
Early-onset de novo donor-specific anti-HLA antibodies may contribute to poor graft function following haploidentical transplantation for myelodysplastic syndrome: a rare case presentation4
Neutrophil-to-lymphocyte ratio half reduction as a surrogate of molecular response in polycythemia vera treated with ropeginterferon alfa-2b4
Antihuman T lymphocyte porcine immunoglobulin combined with cyclosporine as first-line immunosuppressive therapy for severe aplastic anemia in China: a large single-center, 10-year retrospective study4
Is less more? Intravenous immunoglobulin for pediatric immune thrombocytopenia3
Twelve-month follow-up of a real-world, noninterventional study evaluating the impact of emicizumab on bleeding episodes, joint health, and quality of life in people with hemophilia A3
Targeting an elevated FVIII level using personalized rurioctocog alfa pegol prophylaxis in specific patient populations with hemophilia A: post hoc subanalysis of the randomized, phase 3 PROPEL3
Mogamulizumab plus etoposide in the management of mycosis fungoides with blood involvement: a case report3
Mechanisms of resistance to histone deacetylase inhibitors in acute leukemia3
Vedolizumab for second-line treatment of steroid-refractory gastrointestinal late acute graft-versus-host disease3
Safety of venetoclax in real-world experience: data from the French national database of pharmacovigilance through all indications in hematological malignancies over 5 years3
Avatrombopag for the salvage treatment of platelet transfusion refractoriness3
Significance of whole-blood EBV DNA status in T/NK-cell lymphoma-associated hemophagocytic lymphohistiocytosis: a single-center retrospective analysis3
Predicting cytomegalovirus infection and graft-versus-host disease using QuantiFERON-CMV and Monitor in pediatric transplants: a proof-of-concept study3
Development of a nomogram to predict the risk of secondary failure of platelet recovery in patients with β-thalassemia major after hematopoietic stem cell transplantation: a retrospective study3
Relapsed/refractory pure red cell aplasia in chronic lymphocytic leukemia successfully treated with acalabrutinib: a case report and review of the literature3
A retrospective real-world study assessing diagnostic pattern of light-chain amyloidosis in Japan based on data from the medical data vision claims database3
Treatment of multiple myeloma with selinexor: a review3
Pharmacokinetics, pharmacodynamics, safety, and efficacy of crizanlizumab in patients with sickle cell disease: final results from the phase II SOLACE-adults study3
Research advances on short-chain fatty acids in gastrointestinal acute graft-versus-host disease3
Outcomes in participants switching from FVIII replacement therapy to efanesoctocog alfa prophylaxis in XTEND-1: a post hoc analysis3
Recent advances in CAR-T therapy for the treatment of acute myeloid leukemia3
Real-world experience with tisagenlecleucel for the treatment of relapsed or refractory diffuse large B-cell lymphoma in Korea3
The efficacy and safety of third-party umbilical blood/umbilical cord mesenchymal stem cell assisted related haploid hematopoietic stem cell transplantation in pediatric patients with acute leukemia: 2
Recombinant von Willebrand factor for von Willebrand disease: mechanism of action and clinical application2
Immunoglobulin treatment and clinical outcomes: data from the Ontario Immunoglobulin Treatment program multicenter case registry2
Design of an international, phase IV, open-label study of simoctocog alfa in women/girls with hemophilia A undergoing surgery (NuDIMENSION)2
Progress and prospect of ASCT combined with CAR-T therapy in the treatment of multiple myeloma2
Next-generation sequencing of circulating tumor DNA in cerebrospinal fluid for detecting gene mutations in central nervous system lymphoma patients2
The clinical utility and prognostic value of next-generation sequencing for measurable residual disease assessment in acute myeloid leukemia2
Outcomes and management of invasive procedures in participants with hemophilia A post gene therapy: a post hoc analysis of the GENEr8-1 phase III trial2
Cost-effectiveness of acalabrutinib monotherapy or with obinutuzumab versus chemoimmunotherapy for untreated chronic lymphocytic leukemia in China2
Cost-effectiveness analysis of axicabtagene ciloleucel as a second-line treatment for diffuse large B-cell lymphoma in China and the United States2
Infrastructural considerations of implementing gene therapy for hemophilia in the Nordic context2
Experience in the management of patients with HTLV-1 positive adult T-cell leukemia/lymphoma in a Latin American center2
Clinical features and treatment of newly diagnosed multiple myeloma with secondary myelofibrosis: a retrospective study2
An occurrence of eosinophilic folliculitis and alopecia associated with a sustained complete response to mogamulizumab in Sézary syndrome: a case report2
Exploring the interchangeable roles of fibrinogen and FIBTEM in patients with sepsis2
Ibrutinib oral suspension bioavailability and compatibility for optimal enteral administration route2
Effect of BCR::ABL1 transcript type and droplet digital polymerase chain reaction on successful treatment-free remission in chronic myeloid leukemia patients who discontinued tyrosine kinase in2
Real-world patient characteristics and treatment patterns of polycythemia vera in Taiwan between 2016 and 2017: a nationwide cross-sectional study2
Recent advances of CAR-T cells in acute myeloid leukemia2
Clinical outcomes of high-risk patients with polycythemia vera after suboptimal response to first-line therapy who switched to ruxolitinib versus nonswitchers: results from the PV-Switch study2
Real-world use of recombinant porcine sequence factor VIII in the treatment of acquired hemophilia A: EU PASS2
Efficacy and safety of damoctocog alfa pegol prophylaxis in patients ⩾40 years with severe haemophilia A and comorbidities: post hoc analysis from the PROTECT VIII study2
Improved survival outcomes with anakinra over etoposide-based therapies for the management of adults with hemophagocytic lymphohistiocytosis: a retrospective multicenter research network study2
The impact of clinical manifestations on the prognosis of diffuse large B-cell lymphoma2
Systematic literature review of the indirect costs and humanistic burden of β-thalassemia2
The history of oral decitabine/cedazuridine and its potential role in acute myeloid leukemia2
Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in hematologic malignancies: a living systematic review on comparative studies2
Prophylaxis for von Willebrand disease: Is it time for parity with established practice in hemophilia A?2
Efficacy of emicizumab in patients with severe haemophilia A without factor VIII inhibitors in Germany: evaluation of real-life data documented by the smart medication eDiary2
A nomogram based on InLDH and InNLR for predicting disseminated intravascular coagulation in patients with heat stroke2
Genetic lesions and targeted therapy in Hodgkin lymphoma2
0.040020942687988